RXi’s strategic acquisition of OPKO Health’s RNAi-related assets in 2013 not only provides for numerous development opportunities but also substantially expands our intellectual property portfolio.
The portfolio includes patents families with claims relating to important biological targets, including vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1-alpha (HIF-1-alpha), intracellular adhesion molecule 1 (ICAM-1), angiopoietin 2 (Ang2), and complement component 3 (C3). These molecules are believed to play an important role in diseases of the eye, cancer, immune disorders, and inflammatory diseases. RXi Pharmaceuticals’ access to these well-defined patented siRNA sequences could potentially be adapted and optimized for delivery with our self-delivering platform thereby eliminating the need for special formulations to achieve clinical efficacy.
For example, early testing has been done on the sequence of Bevasiranib (formerly known as Cand5): initially developed by OPKO Ophthalmologics, a siRNA-based anti-angiogenic agent proposed for the treatment of wet AMD. Scientists at RXi made modifications to the original sequence turning it into a self-delivering (sd-rxRNA) compound.
Acquired estate provides multiple development opportunities
- Novel potent sd-rxRNA compounds targeting VEGF for potential intra-ocular therapy for age-related macular degeneration
- Other targets - discovery stage efforts ongoing